Edgewise Therapeutics Inc (EWTX NASDAQ) stock market data APIs
$12.9044
0.08(0.6%)
as of July 1, 2025
Try our APIs with
free plan!
Edgewise Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Prev. Close
12.9044
Open
12.9834
High
13.3004
Low
12.6224
52 wk Range
10.6-38.12
Market Cap
1 379 M
Shares Outstanding
105 M
EPS
-0.43
Beta
0.291
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Edgewise Therapeutics Inc data using free add-ons & libraries
Get Edgewise Therapeutics Inc Fundamental Data
Edgewise Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -167 928 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.4211
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Edgewise Therapeutics Inc News
New
Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush
Wedbush analyst Laura Chico lowered the firm’s price target on Edgewise Therapeutics (EWTX) to $35 from $40 and keeps an Outperform rating on the shares. Edgewise said the FDA has deemed CANYON data...
RBC Capital reiterates outperform rating on Edgewise stock amid BMD progress
Investing.com - RBC Capital maintained its Outperform rating and $48.00 price target on Edgewise Therapeutics (NASDAQ:EWTX) stock on Friday, highlighting the company’s progress with its sevasemten...
Edgewise Therapeutics Reports 'Positive' 3-Year Becker Data, Phase 2 Duchenne Muscular Dystrophy Findings for Sevasemten
Edgewise Therapeutics (EWTX) said Thursday its new long-term data from an open-label study showed su PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Edgewise reports positive results for muscular dystrophy drug
BOULDER, Colo. - Edgewise Therapeutics (NASDAQ:EWTX), a $1.52 billion market cap biotech company with a robust financial position and more cash than debt, announced Thursday that its experimental drug...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
